Beti Todorovska, Nenad Joksimovic, Viktorija Caloska-Ivanova, Magdalena Dimitrova-Genadieva, Meri Trajkovska, Elena Curakova, Sanja Kiprijanovska, Beti Zafirova-Ivanovska and Vladimir Serafimoski
Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon. 2011;11(12):986-992.
25. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
26. Ghany MG, Nelson DR, Strader DB, et al. American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology
S. Dražilová, J. Kinčeková, Ľ. Beňa, M. Zachar, M. Švajdler, A. Königová, M. Janičko and P. Jarčuška
., Porubcová, J., Ševčíková, Z. (2009): Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol. Res., 105(4): 1067–1076. DOI: 10.1007/s00436-009-1520-z http://dx.doi.org/10.1007/s00436-009-1520-z
 Dubinský, P., Svobodová, V., Turčeková, Ľ., Literák, I., Martínek, K., Reiterová, K., Kolářová, L., Klimesš, J., Mrlík, V. (1999): Echinococcus multilocularis in Slovak Republic: The first record in red foxes (Vulpes vulpes). Helminthologia, 36(2): 105
Ming-hui Li, Yao Xie, Yao Lu, Guo-hua Qiu, Lu Zhang, Ge Shen, Li-wei Zhuang, Ju-long Hu, Jian-ping Dong, Cai-qin Mu, Lei-ping Hu, Li-jun Chen, Xing-hong Li, Min Yang, Yun-zhong Wu, Hui Zhao, Shu-jing Song, Jun Cheng and Dao-zhen Xu
, Antonaci S. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hepat 2008; 15:300-304.
36. Tsubota A, Satoh K, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, et al. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. World J Gastroenterol 2008; 14:7220-7224.
37. Ferenci P, Laferl H, Scherzer TM, Gschwantler
Vuk R. Vukovic, Dejan Baskic, Zeljko Mijailovic and Predrag Djurdjevic
, Wedemeyer H and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.
8. Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and SustainedViralResponse in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon 2011; 11(12): 968-74.
9. Feuerstadt P, Bunim AL, Garcia H et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51(4): 1137-43.
assessment of chronic viral hepatitis. J Hepatol. 1996; 25:649-54.
28. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut. 2007; 56:699-705.
29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008; 47
Maria Nițescu, Cristina Vâjâitu, Oana Săndulescu, Adrian Streinu-Cercel, Daniela Pițigoi, Liliana Lucia Preoțescu and Anca Streinu-Cercel
clearance of hepatitis C virus infection. J Viral Hepat. 2012 Mar;19(3):173-81. DOI: 10.1111/j.1365-2893.2011.01497.x
10. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul;139(1):120-9 e18.
11. Gheorghe L, Rugina S, Dumitru IM, Franciuc I, Martinescu A, Balas I. HLA class II alleles in Romanian patients with chronic hepatitis C
Angelica Stavar, Irina-Magdalena Dumitru and S Rugina
Introduction: Direct-acting antiviral agents (DAA) have a direct action in chronic hepatitis C, their addition to the standard therapy with interferon alfa2 (IFN) and ribavirin (RBV) significantly improving the sustained virologic response (SVR) in this disease. Objective: The study analyses the results of triple therapy inclduign DAA in terms of tolerability and efficiency. Material and method: We selected a lot of 24 patients who concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. In all the patients clinical and paraclinical assesment was performed including laboratory tests, fibroscan, echography, etc.
Results: The duration of the therapy consisting in association of DAA to the standard treatment was 3 months and led to a remarkable result represented by a high rate of negativation of viremia (83.3%). Among the adverse reactions recorded, the most important were: anemia 17 patients (70.8%), leucopenia 10 patients (41.6%), thrombocitopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12,5%); hyperuricemia 8 patients (33,3%), hypocalcemia 4 patients (16.6%), loss of weight 4 patients (16,6%), anal pruritus (16,6%); among the 24 patients, 2% did not exhibit any adverse reactions.
Conclusions: Despite of the various adverse reactions recorded, the triple therapy consisting in DAA added to the standard treatment proves its utility, and the high rates of sustained viral reaction justifies its utilization. It is necessary to increase the number of patients who benefit from the advantages of triple therapy, which, after becoming larger available, could become a new standard therapy in patients with viral chronic hepatitis.
Irina Magdalena Dumitru, Eugen Dumitru, Liliana Ana Tuta and Sorin Rugina
the rate of virological response in HIVHCV- coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther. 13(7), 953-957.
9. Martin-Carbonero, L., Soriano, V., Valencia, E., Garcia-Samaniego, J., Lopez, M. & Gonzalez- Lahoz, J. (2001). Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 17(16), 1467-1471. doi: 10.1089/08892220152644160.
10. Mira, J.A., Lopez-Cortes, L.F., Barreiro, P., Tural, C., Torres
. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV Virus Taxonomy Profile: Flaviviridae. J Gen Virol. 2017;98(1):2-3. DOI: 10.1099/jgv.0.000672
5. Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J Gen Virol. 2016;97(11):2894-907. DOI: 10.1099/jgv.0.000612
6. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N
Nikolai T. Vatev, Mariyana V. Stoycheva, Andrey I. Petrov and Maria V. Atanasova
1. Radev M. General issues of infectious diseases. In: Iliev V, ed. Infectology. Sofi a: Professor M Drinov Publishing House; 2011;4:312 (in Bulgarian).
2. Yochev S. Viral hepatitis А. In: Yochev S, ed. Infectious diseases. Plovdiv: Raykov Press; 2007;2:122 (in Bulgarian).
3. World Health Organization. The immunological basis for immunization series. Module 18: Hepatitis A. Geneva; February 2011:3.
4. WHO. Recommended surveillance standard of acute viral hepatitis. 2002. http